Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ingenol mebutate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-15 of 15 for your search:
Start Over
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LP0041-21, NCT01541553
Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LP0041-22, 2011-005018-13, NCT01600014
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LP0041-64, 2012-002863-88, NCT01787383
Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LP0085-1000, NCT01803477
Safety and Efficacy of Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days in Subjects With Actinic Keratosis
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LP0105-1012, NCT01820260
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PEP005-002, 2005/153, NCT00108121
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PEP005-003, 2005/154, NCT00108134
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PEP005-009, NCT00432185
PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PEP005-037, NCT01325688
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LP0041-02, NCT01387711
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
Phase: Phase I
Type: Diagnostic, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LP0041-03, NCT01449513
Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LP0084-68, NCT01703078
Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 13-0026, NCT01836367
Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LP0041-62, NCT01892137
Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions
Phase: No phase specified
Type: Treatment
Status: Closed
Age: 18 to 89
Sponsor: Other
Protocol IDs: STU68227, NCT01735942
Start Over